Abstract
Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome. Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes. While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase. In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed. Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.
Keywords: Protein tyrosine phosphatase inhibitor, Shp2, PTP1B, Cdc14, PRL-3, LMW-PTP, Cdc25, eya
Current Pharmaceutical Design
Title: Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
Volume: 16 Issue: 16
Author(s): Latanya M. Scott, Harshani R. Lawrence, Said M. Sebti, Nicholas J. Lawrence and Jie Wu
Affiliation:
Keywords: Protein tyrosine phosphatase inhibitor, Shp2, PTP1B, Cdc14, PRL-3, LMW-PTP, Cdc25, eya
Abstract: Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome. Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes. While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase. In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed. Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.
Export Options
About this article
Cite this article as:
M. Scott Latanya, R. Lawrence Harshani, M. Sebti Said, J. Lawrence Nicholas and Wu Jie, Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery, Current Pharmaceutical Design 2010; 16 (16) . https://dx.doi.org/10.2174/138161210791209027
DOI https://dx.doi.org/10.2174/138161210791209027 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptide-Mediated Cellular Delivery of Oligonucleotide-Based Therapeutics In Vitro: Quantitative Evaluation of Overall Efficacy Employing Easy to Handle Reporter Systems
Current Pharmaceutical Design Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Incorporating Fatty Acid-Modified Polyethylenimine
Current Pharmaceutical Biotechnology Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis
Current Medicinal Chemistry ABC Transporters and the Blood-Brain Barrier
Current Pharmaceutical Design Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Current Pharmaceutical Design Development of 11β -HSD1 Inhibitors for the Treatment of Type 2 Diabetes
Mini-Reviews in Medicinal Chemistry Structure Based Design of 11β-HSD1 Inhibitors
Current Pharmaceutical Biotechnology Intestinal Immunomodulation. Role of Regulative Peptides and Promising Pharmacological Activities
Current Pharmaceutical Design Depression Under the Perspective of Oxytocin
Central Nervous System Agents in Medicinal Chemistry Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry The Impact of Crystallographic Data for the Development of Machine Learning Models to Predict Protein-Ligand Binding Affinity
Current Medicinal Chemistry Multitarget Network Strategies to Influence Memory and Forgetting: The Ras/Mapk Pathway as a Novel Option
Mini-Reviews in Medicinal Chemistry Targeted Inhibition of Angiogenic Factors in AIDS-related Disorders
Current Drug Targets - Infectious Disorders Physiological Basis for Contractile Dysfunction in Heart Failure
Current Pharmaceutical Design Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands
Current Topics in Medicinal Chemistry